GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Radiopharm Theranostics Ltd (ASX:RAD) » Definitions » Buildings And Improvements

Radiopharm Theranostics (ASX:RAD) Buildings And Improvements : A$0.00 Mil (As of Dec. 2024)


View and export this data going back to 2021. Start your Free Trial

What is Radiopharm Theranostics Buildings And Improvements?


Radiopharm Theranostics Buildings And Improvements Historical Data

The historical data trend for Radiopharm Theranostics's Buildings And Improvements can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Radiopharm Theranostics Buildings And Improvements Chart

Radiopharm Theranostics Annual Data
Trend Jun22 Jun23 Jun24
Buildings And Improvements
- - -

Radiopharm Theranostics Semi-Annual Data
Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24
Buildings And Improvements Get a 7-Day Free Trial - - - - -

Radiopharm Theranostics Buildings And Improvements Calculation

Buildings are typically valued at the time of acquisition or construction.  Broker and architect fees, permits, etc. can be covered within this category.  Building components, such as a roof, are normally recorded separately in an asset register since the value and useful lives of these components equal much less than the building itself.

Building improvements that extend the useful life of a building will fall into the category of “building improvements” and should be capitalized.  Improvements are commonly recorded at acquisition cost.  Building improvement examples include roofing, remodeling, replacements, etc.


Radiopharm Theranostics Business Description

Traded in Other Exchanges
Address
62 Lygon Street, Level 3, Carlton South, Melbourne, VIC, AUS, 3053
Radiopharm Theranostics Ltd is an Australian based clinical-stage radiotherapeutics company which is targeting cancer. The company has a pipeline of around four licensed platform technologies, with diagnostic and therapeutic applications in both pre-clinical and clinical stages of development. The company is engaged in research, development and commercialization of health technologies.

Radiopharm Theranostics Headlines

No Headlines